



ACTL7B Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP16511a

Specification

ACTL7B Antibody (N-term) Blocking Peptide - Product Information

Primary Accession <u>O9Y614</u>

ACTL7B Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 10880

Other Names

Actin-like protein 7B, Actin-like-7-beta, ACTL7B

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ACTL7B Antibody (N-term) Blocking Peptide - Protein Information

Name ACTL7B

Cellular LocationCytoplasm, cytoskeleton.

Tissue Location

Detected only in the testis and, to a lesser extent, in the prostate.


ACTL7B Antibody (N-term) Blocking Peptide - Protocols

ACTL7B Antibody (N-term) Blocking Peptide - Background

The protein encoded by this gene is a member of a family of actin-related proteins (ARPs) which share significant amino acidsequence identity to conventional actins. Both actins and ARPs havean actin fold, which is an ATP-binding cleft, as a common feature. The ARPs are involved in diverse cellular processes, includingvesicular transport, spindle orientation, nuclear migration and chromatin remodeling. This gene (ACTL7B), and related gene, ACTL7A, are intronless, and are located approximately 4 kb apart in ahead-to-head orientation within the familial dysautonomia candidateregion on 9q31. Based on mutational analysis of the ACTL7B gene inpatients with this disorder, it was concluded that it is unlikelyto be involved in the pathogenesis of dysautonomia. Unlike ACTL7A, the ACTL7B gene is expressed predominantly in the testis, however, its exact function is not known.

ACTL7B Antibody (N-term) Blocking Peptide - References

Humphray, S.J., et al. Nature 429(6990):369-374(2004)Hisano, M., et al. Nucleic Acids Res. 31(16):4797-4804(2003)Chadwick, B.P., et al. Genomics 58(3):302-309(1999)Schafer, D.A., et al. Annu. Rev. Cell Dev. Biol. 15, 341-363 (1999):





Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides